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S3
Diethyl 3-(N-hydroxyacetamido)propylphosphonate (12). To a solution of
General Procedure for the Preparation of the Ether Ligands 13a-d.
To a solution of 12 (1 eq) in THF (3.9 mL/mmol of 12) at 0°C was added sodium hydride (1.1 eq) in suspension in THF (1.2 mL/mmol of 12). The reaction mixture was allowed to room temperature and the desired arylbromide (1.1-2.0 eq) was added. Then, the mixture was heated at S9 70°C for 2-24h. NaH was neutralized with water at 0°C, the organic layer was washed with H 2 O and the aqueous phase was extracted three times with CH 2 Cl 2 . The combined organic layers were dried over MgSO 4 , filtered and concentrated in vacuo. Purification by flash chromatography on silica gel (EtOAc/MeOH) gave the expected ether. 
Diethyl 3-(N-(phenethyloxy)acetamido)propylphosphonate (13a).
Diethyl 3-(N-(3-phenylpropoxy)acetamido)propylphosphonate (13b)
.
Diethyl 3-(N-(4-isopropylbenzyloxy)acetamido)propylphosphonate (13c
Diethyl 3-(N-(benzyloxy)-2-phenylacetamido)propylphosphonate (17a).
To a solution of diethyl 3-(benzyloxyamino)propylphosphonate 16 (590 mg, 1.96 mmol) in CH 2 Cl 2 (10 mL) at 0°C were added triethylamine (0.33 mL, 2.37 mmol, 1.2 eq) and phenylacetyl chloride (0.36 mL, 2.70 mmol, 1.4 eq). The resulting mixture was stirred overnight at room temperature. The organic layer was washed successively with water, saturated NaHCO 3 , and water, and dried over 
Diethyl 3-(N-hydroxy-2-phenylacetamido)propylphosphonate (18a). To a solution of 17a
(411 mg, 0.98 mmol) in methanol (20 mL) and ethyl acetate (2 mL) was added 10% Pd/C (cat.). 
Diethyl 3-(N-hydroxy-4-phenylbutanamido)propylphosphonate (18b). To a solution of 17b
(690 mg, 1.54 mmol) in methanol (20 mL) was added 10% Pd/C (cat. 
Diethyl 3-(N-(benzyloxy)cyclohexanecarboxamido)propylphosphonate (20). A solution of 19
(210 mg, 0.90 mmol) in THF (10 mL) was added dropwise to a suspension of sodium hydride 60% in oil (44 mg, 1.10 mmol, 1.2 eq) in THF (5 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and a solution of 10 (288 mg, 1.11 mmol, 1.2 eq) in THF (5 mL) was added. The resulting mixture was stirred overnight at 70°C. Assay Reagent (Cytoskeleton, Denver, CO) with γ-globulins (Sigma-Aldrich) as the standard.
The protein was visualized via Coomassie stained SDS-PAGE.
Mtb Dxr spectrophotometric assay
Dxr activity was evaluated at 37 o C by spectrophotometrically monitoring the enzyme catalyzed oxidation of NADPH, as described previously. 6 To determine the mode of inhibition with respect to DXP, the assay was performed with either 150 µM NADPH (for FR900098) or 30 µM NADPH (for compound 8). The enzyme was preincubated with each inhibitor for 10 minutes (37 o C) prior to addition of substrate. For the mechanism relative to NADPH, the assays were performed with 47 µM DXP. Here, the enzyme was preincubated with the inhibitor for 10 minutes prior to addition of NADPH, and an additional 5 minutes before addition of DXP. All assays were performed in duplicate. Lineweaver-Burk plots were generated using GraphPad PRISM version 4.00 for Windows (GraphPad Software Inc., San Diego, CA). IC 50 s were determined via nonlinear regression analysis of standard dose-response plots using GraphPad PRISM.
Supplementary Figure 1 . Kinetic characterization of inhibitor activity. A) Relative inhibition by compounds 3-9 at 100 µM concentration. B) through H) Dose-response plots obtained using the indicated inhibitors. The LineweaverBurk plots (I and J) reveal that FR900098 is a competitive inhibitor relative to DXP and an uncompetitive inhibitor with respect to NADPH, indicating that the inhibitor binds to the enzyme only after NADPH is bound.
Molecular Docking. Docking studies were performed using the Glide tool in Schrödinger, suite 
S16
positional constraint of the phosphorus and a CORE constraint were used. Compounds to be docked were built and minimized using Maestro, and molecular docking was performed in extra precision (XP) mode.
Mtb MIC Assay. The assay was performed as described. 7 A stock culture of Mtb H37Rv
(ATCC 27294) was grown to OD 0.5 in Middlebrook 7H9 broth (Difco) supplemented with 0.05% Tween-80, 0.2% glycerol, and albumin/NaCl/glucose (ADC) complex. The culture was diluted 1:1000 in 7H9-based medium before aliquoting 50 µL into each well of a 96-well plate.
The inhibitors were dissolved in DMSO to make stock solutions of 50 mg/mL. Inhibitors were added to the first row of wells of the 96-well plate with 100 µL of 7H9-based medium. After pipet mixing and use of a multichannel pipet, 50 µL was removed from each well in the first row and added to the second row. 2-Fold dilution in this manner was carried out to give eight dilutions of each inhibitor. The plates were incubated for 2 weeks at 37 °C, and the MIC 99 values were read macroscopically using an inverted plate reader. Each measurement was made three independent times.
